HK1137509A1 - Circulating tumor cell assay - Google Patents

Circulating tumor cell assay

Info

Publication number
HK1137509A1
HK1137509A1 HK10100979.3A HK10100979A HK1137509A1 HK 1137509 A1 HK1137509 A1 HK 1137509A1 HK 10100979 A HK10100979 A HK 10100979A HK 1137509 A1 HK1137509 A1 HK 1137509A1
Authority
HK
Hong Kong
Prior art keywords
tumor cell
circulating tumor
cell assay
assay
circulating
Prior art date
Application number
HK10100979.3A
Other languages
English (en)
Chinese (zh)
Inventor
‧瓜爾貝托
‧羅伯茨
‧梅爾文
‧雷伯萊特
‧錢尼斯
‧康奈利
‧特斯塔潘
Original Assignee
輝瑞產品公司
維利迪克斯有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 輝瑞產品公司, 維利迪克斯有限責任公司 filed Critical 輝瑞產品公司
Publication of HK1137509A1 publication Critical patent/HK1137509A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK10100979.3A 2006-06-02 2010-01-29 Circulating tumor cell assay HK1137509A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81081106P 2006-06-02 2006-06-02
PCT/IB2007/001483 WO2007141626A1 (fr) 2006-06-02 2007-05-29 Analyse de cellules tumorales circulantes

Publications (1)

Publication Number Publication Date
HK1137509A1 true HK1137509A1 (en) 2010-07-30

Family

ID=38476880

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100979.3A HK1137509A1 (en) 2006-06-02 2010-01-29 Circulating tumor cell assay

Country Status (20)

Country Link
US (4) US8940493B2 (fr)
EP (1) EP2027470B1 (fr)
JP (1) JP4943504B2 (fr)
KR (3) KR101467136B1 (fr)
CN (1) CN101600966B (fr)
AU (1) AU2007255110B8 (fr)
BR (1) BRPI0712225A8 (fr)
CA (1) CA2653745C (fr)
DK (1) DK2027470T3 (fr)
ES (1) ES2397971T3 (fr)
HK (1) HK1137509A1 (fr)
IL (1) IL195577A (fr)
MX (1) MX2008015425A (fr)
NZ (1) NZ573187A (fr)
PL (1) PL2027470T3 (fr)
PT (1) PT2027470E (fr)
RU (1) RU2429486C2 (fr)
SI (1) SI2027470T1 (fr)
WO (1) WO2007141626A1 (fr)
ZA (1) ZA200810203B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
WO2011050103A1 (fr) 2009-10-21 2011-04-28 The Scripps Research Institute Méthodes d'utilisation de cellules non rares pour détecter des cellules rares
RU2429486C2 (ru) 2006-06-02 2011-09-20 Пфайзер Продактс Инк. Анализ циркулирующих опухолевых клеток
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009045389A2 (fr) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Marqueurs biologiques de prédiction de la réponse anti-cancéreuse aux inhibiteurs de la kinase du récepteur 1 du facteur de croissance insulinomimétique de type 1 (igf-1r)
US7939272B2 (en) 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090258365A1 (en) * 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
EA029178B1 (ru) 2008-12-12 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
WO2011083391A2 (fr) * 2010-01-05 2011-07-14 Pfizer Inc. Biomarqueurs pour une thérapie du cancer par un anti-igf-1r
ES2634220T3 (es) * 2010-10-14 2017-09-27 Janssen Diagnostics, Llc Métodos y kits para la detección de células tumorales circulantes en pacientes pancreáticos utilizando reactivos poliespecíficos de captura y coctel de detección
US20140308669A1 (en) * 2011-01-24 2014-10-16 Epic Science, Inc. Methods for obtaining single cells and applications of single cell omics
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
ES2799581T3 (es) * 2011-07-21 2020-12-18 Menarini Silicon Biosystems Spa Ensayo para capturar y detectar células de mieloma múltiple circulantes de la sangre
WO2013036620A1 (fr) * 2011-09-06 2013-03-14 Becton, Dickinson And Company Procédés et compositions destinés à la détection cytométrique de cellules cibles rares dans un échantillon
EP4001426A1 (fr) 2012-08-13 2022-05-25 The Regents of The University of California Procédés et systèmes de détection de composants biologiques
BR112015007528A2 (pt) * 2012-10-05 2018-09-04 Genentech Inc método para prever a resposta, para prever a responsividade, para identificar e para tratar um paciente que tem uma disfunção inflamatória gastrointestinal.
RU2636352C2 (ru) * 2012-10-26 2017-11-22 Флуидигм Кэнада Инк. Способ и система для клеточного анализа с помощью массовой цитометрии
US9396532B2 (en) * 2012-11-15 2016-07-19 Siemens Healthcare Diagnostics, Inc. Cell feature-based automatic circulating tumor cell detection
EP2948776B8 (fr) 2013-01-25 2020-02-26 Xcell Biosciences, Inc. Procédés, compositions, trousses et systèmes pour l'enrichissement sélectif de cellules cibles
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3060680B1 (fr) 2013-10-21 2019-02-27 The General Hospital Corporation Méthodes se rapportant aux amas de cellules tumorales circulantes et au traitement du cancer
CN103630440A (zh) * 2013-11-28 2014-03-12 武汉大学 一种循环肿瘤细胞的富集方法
US10527624B2 (en) 2014-01-27 2020-01-07 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
RU2678135C1 (ru) * 2014-02-05 2019-01-23 Фуджиребио Диагностикс Аб Композиция и способ для детектирования злокачественного неопластического заболевания
EP3108246B1 (fr) 2014-02-21 2019-10-09 Epic Sciences, Inc. Méthodes pour analyser des cellules circulantes rares
CN103940997B (zh) * 2014-03-21 2017-01-04 上海柏慧康生物科技有限公司 一种乳腺癌循环肿瘤细胞检测系统及试剂盒
KR101656037B1 (ko) * 2014-04-30 2016-09-08 울산과학기술원 희소 세포 분리장치, 희소 세포 분리 방법 및 이를 이용한 희소 세포 검출 방법
EP3160654A4 (fr) 2014-06-27 2017-11-15 The Regents of The University of California Tri activé par pcr (pas)
CN104345052B (zh) * 2014-09-29 2017-10-20 南通市肿瘤医院 一种荧光负染法检测活细胞的方法
CA3001986C (fr) 2014-10-22 2023-02-21 The Regents Of The University Of California Imprimante a microgouttelettes haute definition
EP3253479B1 (fr) 2015-02-04 2022-09-21 The Regents of The University of California Séquençage d'acides nucléiques contenus dans des entités individuelles par barcoding
CA2981543A1 (fr) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, detection, diagnostic et/ou caracterisation de cellules cancereuses trop-2 positives
KR101701618B1 (ko) 2015-06-23 2017-02-13 국립암센터 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도
RU2616532C1 (ru) * 2015-12-28 2017-04-17 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ оценки чувствительности опухоли к проводимой химиотерапии больных местно-распространенным раком молочной железы
KR102130872B1 (ko) 2016-04-27 2020-07-06 주식회사 엘지화학 고체 시료의 수분 측정 장치, 고체 시료 수분 함량 측정 방법 및 이미드화율 분석 방법
WO2018031691A1 (fr) 2016-08-10 2018-02-15 The Regents Of The University Of California Amplification à déplacement multiple et pcr combinées dans une microgouttelette d'émulsion
CA3047328A1 (fr) 2016-12-21 2018-06-28 The Regents Of The University Of California Sequencage genomique de cellules uniques a l'aide de gouttelettes a base d'hydrogel
US11576424B2 (en) 2017-04-05 2023-02-14 Altria Client Services Llc Susceptor for use with an inductively heated aerosol-generating device or system
EP3606363B1 (fr) 2017-04-05 2021-05-05 Philip Morris Products S.A. Suscepteur destiné à être utilisé avec un dispositif ou un système de production d'aérosol chauffé par induction
US10501739B2 (en) 2017-10-18 2019-12-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
EP3540631A1 (fr) * 2018-03-15 2019-09-18 Siemens Healthcare GmbH Procédé in vitro destiné à la détermination sans marquage d'un type de cellule d'une cellule sanguine blanche
CN109406245A (zh) * 2018-09-12 2019-03-01 中国辐射防护研究院 一种电子线照射对小鼠igf相关蛋白表达影响的检测方法
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
US11667954B2 (en) 2019-07-01 2023-06-06 Mission Bio, Inc. Method and apparatus to normalize quantitative readouts in single-cell experiments
WO2024148280A1 (fr) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Traitement du cancer du sein er+ comprenant une déficience de recombinaison homologue à l'aide d'un inhibiteur de parc

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551435A (en) 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4925788A (en) 1986-10-24 1990-05-15 Immunicon Corporation Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US5108933A (en) 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0891550A1 (fr) 1996-04-05 1999-01-20 The Johns Hopkins University School Of Medicine Procede d'enrichissement de cellules rares
US20020172987A1 (en) 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999041613A1 (fr) 1998-02-12 1999-08-19 Immunivest Methodes et reactifs pour l'isolation rapide et efficace de cellules cancereuses circulantes
US20010018192A1 (en) 1998-02-12 2001-08-30 Terstappen Leon W.M.M. Labeled cells for use as an internal functional control in rare cell detection assays
DE19983691T1 (de) 1998-10-29 2001-11-29 Cell Works Inc Charakterisierung mehrerer Marker von Einzelzellen
AU2876900A (en) 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
JP2001041959A (ja) 1999-05-24 2001-02-16 Toray Ind Inc 癌細胞検出システムおよび癌細胞検出キット
CA2380953A1 (fr) 1999-08-18 2001-02-22 The General Hospital Corporation Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP2004523232A (ja) * 2001-01-23 2004-08-05 プリマゲン ホールディング ベー．フェー． 治療評価の手段と方法
CA2438112A1 (fr) * 2001-02-16 2003-08-07 Immunivest Corporation Methodes et reactifs destines a l'isolement rapide et efficace de cellules cancereuses circulantes
US7863012B2 (en) 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
KR20040030984A (ko) * 2001-08-23 2004-04-09 이뮤니베스트 코포레이션 순환성 종양 세포, 단편 및 잔해의 분석
US6670142B2 (en) * 2001-10-26 2003-12-30 The Regents Of The University Of California Method for screening combinatorial bead library, capturing cells from body fluids, and ligands for cancer cells
PT1461359E (pt) * 2002-01-18 2007-06-29 Pf Medicament Anticorpos anti-igf-ir e suas aplicações
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
KR100825156B1 (ko) * 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 변형된 인간 ｉｇｆ-ｉｒ 항체
KR20080019733A (ko) 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
WO2006041453A1 (fr) 2004-09-30 2006-04-20 Immunivest Corporation Cellules tumorales circulantes (ctc): evaluation de l'apoptose chez les patients presentant un cancer de la prostate
PL1861509T3 (pl) 2005-03-14 2016-01-29 Janssen Diagnostics Llc Sposób predykcji przeżywalności bez progresji i przeżywalności całkowitej przy wizytach kontrolnych w trakcie terapii u pacjentów z rozsianym rakiem piersi wykorzystujący krążące komórki nowotworowe
US20070037173A1 (en) 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
RU2429486C2 (ru) 2006-06-02 2011-09-20 Пфайзер Продактс Инк. Анализ циркулирующих опухолевых клеток
CA2971968C (fr) * 2007-10-24 2019-08-13 Biomarker Strategies, Llc Procedes et dispositifs ameliores pour l'analyse cellulaire

Also Published As

Publication number Publication date
BRPI0712225A2 (pt) 2012-07-24
AU2007255110B8 (en) 2014-04-10
SI2027470T1 (sl) 2013-01-31
AU2007255110A8 (en) 2014-04-10
US20100028915A1 (en) 2010-02-04
RU2429486C2 (ru) 2011-09-20
US8940493B2 (en) 2015-01-27
PT2027470E (pt) 2013-01-28
US20200191793A1 (en) 2020-06-18
ES2397971T3 (es) 2013-03-12
ZA200810203B (en) 2020-05-27
KR101467136B1 (ko) 2014-12-01
MX2008015425A (es) 2008-12-12
DK2027470T3 (da) 2013-02-04
CA2653745C (fr) 2013-11-19
JP4943504B2 (ja) 2012-05-30
RU2008147415A (ru) 2010-06-10
WO2007141626A8 (fr) 2009-01-08
KR20140052081A (ko) 2014-05-02
US20150177252A1 (en) 2015-06-25
EP2027470A1 (fr) 2009-02-25
WO2007141626A1 (fr) 2007-12-13
KR20090023423A (ko) 2009-03-04
KR20130091788A (ko) 2013-08-19
CN101600966A (zh) 2009-12-09
AU2007255110B2 (en) 2014-03-20
CN101600966B (zh) 2014-07-02
AU2007255110A1 (en) 2007-12-13
IL195577A0 (en) 2009-09-01
US20180011103A1 (en) 2018-01-11
PL2027470T3 (pl) 2013-03-29
JP2009539097A (ja) 2009-11-12
CA2653745A1 (fr) 2007-12-13
EP2027470B1 (fr) 2012-11-21
BRPI0712225A8 (pt) 2019-01-22
IL195577A (en) 2012-12-31
NZ573187A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
HK1137509A1 (en) Circulating tumor cell assay
EP2008368A4 (fr) Techniques de partage d'antenne
GB0720484D0 (en) Cells
IL194892A0 (en) Nonseparation assay methods
PL2021778T3 (pl) Nieseparacyjne metody oznaczania
EP2028264A4 (fr) Incubateur de cellules
GB0603160D0 (en) Nucleic acid
GB0713930D0 (en) Novel assay methods
GB0705495D0 (en) Whole blood assay
IL196268A0 (en) Assay methods
GB0503918D0 (en) Cell
GB0723338D0 (en) Prognostic assay
GB0514911D0 (en) T cell memory assay
EP2048223A4 (fr) Puces à cellules
GB0608446D0 (en) Assay
GB0812845D0 (en) Electrochemical assay
GB0725234D0 (en) Electrochemical assays
GB0615813D0 (en) Assay
GB0600960D0 (en) Whole cell biosensor
GB0522564D0 (en) Cells
GB0623892D0 (en) Assay
GB0607462D0 (en) Assay
GB0723137D0 (en) Electrochemical assay
GB0602082D0 (en) Cells
GB0715386D0 (en) Assay

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200527